| News

Kinarus secures capital commitment of 57 million Swiss francs

13.09.2021

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group GEM. This should support the phase II trial for Kinarus’ clinical drug candidate to treat a retinal disease.

Kinarus can fund the phase 2 trial for its clinical drug candidate KIN001 for the treatment of wet macular degeneration with up to 57 million Swiss francs. The biopharmaceutical company headquartered at the Technologiepark Basel has received a corresponding capital commitment from the investment group Global Emerging Markets (GEM). It has a term of 36 months. According to a press release from the company, Kinarus can draw the funds at any time and “within certain limits” during this period. The self-styled “alternative” investment group is based in Luxembourg. It has branches in New York, Paris and the Bahamas.

First, the reverse takeover by Perfect Holding based in Lausanne in the canton of Vaud announced in mid-August is planned to be concluded. Since the sale of its subsidiary Oxygen Aviation in April 2020, Perfect Holding is now just a shell but it is listed on the SIX Swiss Exchange. A reverse takeover can make private companies into listed companies without having to undergo flotation. According to the press release, Kinarus is expected to be listed this year subject to approval of the shareholders and conclusion of the series B financing round.

According to the CEO of Kinarus, Alexander Bausch, this additional capital will help to “broaden the clinical phase 2 portfolio of KIN001 in additional indications of high medical need.” The company further states that it has several patents covering the use of KIN001 in numerous indications. In April, Kinarus started the phase 2 trial KINETIC with KIN001, in which patients hospitalized with COVID-19 are now being treated with KIN001.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

EsoCap impresses investors
Basel Area Business & Innovation, Innovation, Invest

EsoCap impresses investors

EsoCap, a biotech company based in Basel, has concluded a successful funding round. The funds from new and existing investors...

Read More
Plug and Play settles in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Plug and Play settles in the Basel Area

Plug and Play is coming to the canton of Basel-Landschaft. The first founding partner of the innovation promoter from Silicon...

Read More
Bachem builds its largest production building
Basel Area Business & Innovation, Innovation, Invest

Bachem builds its largest production building

Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of...

Read More
Bottneuro advancing personalized Alzheimer’s therapy
Basel Area Business & Innovation, Innovation, Invest

Bottneuro advancing personalized Alzheimer’s therapy

Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of...

Read More
Straumann plans to build innovation center in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Straumann plans to build innovation center in the Basel Area

The Basel-based dental specialist Straumann is planning to construct a new technology and innovation center in Arlesheim in the canton...

Read More
Ontotext opens new office in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Ontotext opens new office in the Basel Area

Ontotext, a company based in New York City and the Bulgarian capital of Sofia, has opened a new location at...

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.